Impact of Adjuvant Radiotherapy on Survival of Patient Cancer

Journal of Clinical Oncology

32, 3939-3947

DOI: 10.1200/jco.2013.54.7893

Citation Report

#	Article	IF	Citations
1	Potential Role for Androgen-Deprivation Therapy and Pelvic Radiation Therapy in Node-Positive Postprostatectomy Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 3926-3929.	0.8	1
2	Adjuvant Radiation for Node-Positive Disease After Prostatectomy: More Good News, but Who Will Listen?. Journal of Clinical Oncology, 2014, 32, 3917-3919.	0.8	5
4	The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer. World Journal of Surgical Oncology, 2015, 13, 312.	0.8	4
5	The biology and treatment of oligometastatic cancer. Oncotarget, 2015, 6, 8491-8524.	0.8	243
6	Response. Journal of the National Cancer Institute, 2015, 107, djv201.	3.0	1
7	RE: Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	1
10	Reply to Jovo BogdanoviÄ‡ and Vuk SekuliÄ‡â€™s Letter to the Editor re: Firas Abdollah, Giorgio Gandaglia, Nazareno Suardi, et al. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. Eur Urol 2015;67:212â€“9. European Urology, 2015, 68, e37-e38.	0.9	2
11	Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A Systematic Review of the Literature. Journal of Urology, 2015, 194, 983-988.	0.2	83
12	Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival. European Urology, 2015, 68, 777-784.	0.9	48
13	External Validation of the Benefit of Adjuvant Radiotherapy for Pathologic N1M0 Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1987-1988.	0.8	12
14	The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer. Current Oncology Reports, 2015, 17, 53.	1.8	7
15	Reply to C.G. Rusthoven et al. Journal of Clinical Oncology, 2015, 33, 1989-1989.	0.8	1
16	Reply to C.G. Rusthoven et al. Journal of Clinical Oncology, 2015, 33, 1990-1991.	0.8	0
17	Low Use of Immediate and Delayed Postoperative Radiation for Prostate Cancer with Adverse Pathological Features. Journal of Urology, 2015, 194, 972-976.	0.2	20
18	Pathologic Lymph Nodeâ€“positive Prostate Cancer: Some Answers â€¦ with Many More Questions. European Urology, 2015, 68, 785-786.	0.9	0
19	What Evidence Do We Need to Support the Use of Extended Pelvic Lymph Node Dissection in Prostate Cancer?. European Urology, 2015, 67, 597-598.	0.9	18
20	Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing Controversies. Prostate Cancer, 2016, 2016, 1-12.	0.4	17
21	Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. Investigative and Clinical Urology, 2016, 57, S155.	1.0	4

#	Article	IF	Citations
22	Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection. Frontiers in Surgery, 2016, 3, 65.	0.6	19
23	Association between very small tumour size and increased cancerâ€specific mortality after radical prostatectomy in lymph nodeâ€positive prostate cancer. BJU International, 2016, 118, 279-285.	1.3	14
24	Lymph node staging in prostate cancer: perspective for the pathologist. Journal of Clinical Pathology, 2016, 69, 1039-1045.	1.0	13
26	Precision management of localized prostate cancer. Expert Review of Precision Medicine and Drug Development, 2016, 1, 505-515.	0.4	6
30	No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy. British Journal of Radiology, 2016, 89, 20150985.	1.0	7
31	Rentabilidad diagnÃ³stica y complicaciones de la linfadenectomÃa ampliada frente a la limitada asociada a prostatectomÃa radical. Actas UrolÃ³gicas EspaÃ±olas, 2016, 40, 75-81.	0.3	2
32	Adapting machine learning techniques to censored time-to-event health record data: A general-purpose approach using inverse probability of censoring weighting. Journal of Biomedical Informatics, 2016, 61, 119-131.	2.5	82
33	The importance of adjuvant therapy in patients with node-positive prostate cancer: A nationwide validation study. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 577-578.	0.8	0
34	Adjuvant radiation with hormonal therapy is associated with improved survival in men with pathologically involved lymph nodes after radical surgery for prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 529.e15-529.e20.	0.8	16
35	Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy. Journal of Clinical Oncology, 2016, 34, 3829-3833.	0.8	7
36	The very-high-risk prostate cancer: a contemporary update. Prostate Cancer and Prostatic Diseases, 2016, 19, 340-348.	2.0	29
37	Predicting survival in nodeâ€positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multiâ€institutional database. International Journal of Urology, 2016, 23, 1000-1008.	0.5	8
38	The Outcome for Patients With Pathologic Node-Positive Prostate Cancer Treated With Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy: A Case-Matched Analysis of pN1 and pN0 Patients. International Journal of Radiation Oncology Biology Physics, 2016, 96, 323-332.	0.4	19
39	Diagnostic yield and complications of extended lymphadenectomy versus limited lymphadenectomy combined with radical prostatectomy. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2016, 40, 75-81.	0.2	0
40	Radiation therapy for urological cancers. Journal of Clinical Urology, 2016, 9, 142-150.	0.1	0
41	Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. European Urology, 2016, 69, 775-787.	0.9	72
42	Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup. Journal of Urology, 2016, 195, 1773-1778.	0.2	37
43	The best of uro-oncology in 2015. European Urology Supplements, 2016, 15, 67-67a.	0.1	0

#	Article	IF	Citations
44	The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. European Urology, 2016, 69, 1142-1148.	0.9	60
45	Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy. European Urology, 2016, 69, 193-196.	0.9	27
46	â€œHit the primaryâ€• A paradigm shift in the treatment of metastatic prostate cancer?. Critical Reviews in Oncology/Hematology, 2016, 97, 231-237.	2.0	18
47	Individualization of Adjuvant Therapy After Radical Prostatectomy for Clinically Localized Prostate Cancer: Current Status and FutureÂDirections. Clinical Genitourinary Cancer, 2016, 14, 12-21.	0.9	7
48	Natural History of Clinical Recurrence Patterns of Lymph Nodeâ€“Positive Prostate Cancer After Radical Prostatectomy. European Urology, 2016, 69, 135-142.	0.9	58
49	Curing Lymph Node Metastasis in Prostate Cancer: The Ongoing Battle Between Improving Surgical Quality and Tumor Biology. European Urology Focus, 2017, 3, 256-257.	1.6	1
50	Management of Prostate Cancer. , 2017, , .		5
51	Re: The Role of Adjuvant Radiotherapy in Pathologically Lymph Node Positive Prostate Cancer. European Urology, 2017, 71, 833-834.	0.9	1
52	The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. European Urology, 2017, 72, 84-109.	0.9	348
53	Radiotherapy in the Management of Prostate Cancer. Medical Radiology, 2017, , 87-112.	0.0	0
54	Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. European Urology, 2017, 72, 689-709.	0.9	73
55	Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence. Therapeutic Advances in Urology, 2017, 9, 73-80.	0.9	11
56	Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. European Urology, 2017, 72, 632-640.	0.9	165
58	Whole pelvis radiotherapy for pathological node-positive prostate cancer. Strahlentherapie Und Onkologie, 2017, 193, 444-451.	1.0	13
59	Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. European Urology, 2017, 72, 910-917.	0.9	21
60	Contemporary Patterns of Care and Outcomes of Men Found to Have Lymph Node Metastases at the Time of Radical Prostatectomy. Journal of Urology, 2017, 198, 1077-1084.	0.2	23
61	ACR Appropriateness CriteriaÂ® Locally Advanced, High-Risk Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 1-10.	0.6	10
62	Postoperative Radiation After Radical Prostatectomy. Seminars in Radiation Oncology, 2017, 27, 50-66.	1.0	4

#	Article	IF	Citations
63	Updated postoperative nomogram incorporating the number of positive lymph nodes to predict disease recurrence following radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2017, 20, 105-109.	2.0	7
64	Extent of Lymphadenectomy at Time of Prostatectomy. Urologic Clinics of North America, 2017, 44, 587-595.	0.8	6
65	Managing Cancer Relapse After Radical Prostatectomy. Urologic Clinics of North America, 2017, 44, 597-609.	0.8	1
66	Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment. World Journal of Urology, 2017, 35, 1833-1839.	1.2	17
67	A House Divided: The Irradiation Versus Prostatectomy Debate Continues. International Journal of Radiation Oncology Biology Physics, 2017, 99, 512-514.	0.4	3
68	Approach to the Patient with High-Risk Prostate Cancer. Urologic Clinics of North America, 2017, 44, 635-645.	0.8	6
70	The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer. Prostate Cancer and Prostatic Diseases, 2017, 20, 85-92.	2.0	48
71	Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with <scp>pN</scp>1 prostate cancer treated with radical prostatectomy. BJU International, 2017, 119, 717-723.	1.3	39
72	The role of adjuvant radiotherapy in pathologically lymph nodeâ€positive prostate cancer. Cancer, 2017, 123, 512-520.	2.0	48
73	Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2017, 97, 526-535.	0.4	35
74	Longâ€term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy. BJU International, 2017, 120, 69-75.	1.3	10
75	The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients. Prostate Cancer and Prostatic Diseases, 2017, 20, 7-11.	2.0	11
76	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2017, 71, 618-629.	0.9	2,497
77	Management of Node-Positive and Oligometastatic Prostate Cancer. Seminars in Radiation Oncology, 2017, 27, 79-86.	1.0	10
78	Early Postoperative Radiotherapy is Associated with Worse Functional Outcomes in Patients with Prostate Cancer. Journal of Urology, 2017, 197, 669-675.	0.2	55
79	Complete Tissue Submission to Increase Lymph Node Detection in Pelvic Lymph Node Packets Submitted for Patients Undergoing Radical Prostatectomy and Radical Cystectomy. International Journal of Surgical Pathology, 2017, 25, 12-17.	0.4	4
80	Pelvic Lymph Node Dissection in Prostate Cancer: Indications, Extent and Tailored Approaches. Urologia, 2017, 84, 9-19.	0.3	25
81	Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. Journal of Clinical Oncology, 2017, 35, 1982-1990.	0.8	76

#	Article	IF	Citations
82	Use of the Electronic Medical Record to Facilitate Intervention for Patients With Rising Prostate-Specific Antigen Values After Radical Prostatectomy: A Feasibility Study. JCO Clinical Cancer Informatics, 2017, 1, 1-6.	1.0	0
83	Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection. Clinical Cancer Research, 2018, 24, 2342-2349.	3.2	12
84	Re: Karim A. Touijer, Robert Jeffery Karnes, Niccolo Passoni, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol 2018;73:890â€“6.. European Urology, 2018, 74, e15-e17.	0.9	0
85	Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in nodeâ€positive prostate cancer patients: External validation on a multiâ€institutional database. International Journal of Urology, 2018, 25, 574-581.	0.5	8
86	Prediction of Biochemical Recurrence Following Radiotherapy among Patients with Persistent PSA after Radical Prostatectomy: A Single-Center Experience. Urologia Internationalis, 2018, 101, 47-55.	0.6	7
87	First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 239.e17-239.e25.	0.8	12
89	Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection. European Urology, 2018, 74, 253-256.	0.9	48
90	Discord Among Radiation Oncologists and Urologists in the Postoperative Management of High-Risk Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 739-746.	0.6	5
91	Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. European Urology, 2018, 73, 890-896.	0.9	87
92	Identifying candidates for superâ€extended staging pelvic lymph node dissection among patients with highâ€risk prostate cancer. BJU International, 2018, 121, 421-427.	1.3	24
93	Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nature Reviews Clinical Oncology, 2018, 15, 168-182.	12.5	7
94	Patterns of Care of Node-Positive Prostate Cancer Patients Across the United States: A National Cancer Data Base Analysis. Clinical Genitourinary Cancer, 2018, 16, 35-41.e1.	0.9	4
95	Lymphadenectomy in Gleason 7 prostate cancer: Adherence to guidelines and effect on clinical outcomes. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 13.e11-13.e18.	0.8	3
96	Nodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment. European Urology, 2018, 73, 897-898.	0.9	1
97	Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. European Urology, 2018, 74, 99-106.	0.9	28
98	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. European Urology, 2018, 73, 436-444.	0.9	60
99	Adjuvant radiotherapy and mortality in lymph node-positive prostate cancer. AME Medical Journal, 0, 3, 31-31.	0.4	1
102	Difference in Frequency and Distribution of Nodal Metastases Between Intermediate and High Risk Prostate Cancer Patients: Results of a Superextended Pelvic Lymph Node Dissection. Frontiers in Surgery, 2018, 5, 52.	0.6	10

#	Article	IF	Citations
104	Genitourinary Pathology Reporting Parameters Most Relevant to the Medical Oncologist. Surgical Pathology Clinics, 2018, 11, 877-891.	0.7	0
105	RADICAL(S) Radiotherapy Post-prostatectomy, Current and Future Practice. Clinical Oncology, 2018, 30, 793-797.	0.6	0
109	Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. European Urology Oncology, 2018, 1, 531-537.	2.6	106
111	Radiotherapy for Prostate Cancer Patients with Pelvic Lymph Node Metastasis. , 2018, , 85-93.		0
112	Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 2018, 129, 377-386.	0.3	39
113	Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Radiation Oncology, 2018, 13, 37.	1.2	54
115	Reply to Pim J. van Leeuwen and Henk G. van der Poel's Letter to the Editor re: Karim A. Touijer, Robert J. Karnes, Niccolo Passoni, et al. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol 2018;73:890â€“6.. European Urology, 2018, 74, e18-e19.	0.9	0
116	Extended field radiotherapy measurements in a single shot using a BaFBr-based OSL-film. Physics in Medicine and Biology, 2019, 64, 165007.	1.6	6
117	Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients. Journal of Cancer, 2019, 10, 2237-2242.	1.2	15
118	11C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities. Advances in Radiation Oncology, 2019, 4, 659-667.	0.6	12
119	Impact of GAS5 genetic polymorphism on prostate cancer susceptibility and clinicopathologic characteristics. International Journal of Medical Sciences, 2019, 16, 1424-1429.	1.1	23
120	Long-Term Mortality in Patients with Positive Lymph Nodes at the Time of Radical Prostatectomy. Urologia Internationalis, 2019, 103, 427-432.	0.6	6
121	Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy. Radiation Oncology, 2019, 14, 198.	1.2	6
122	Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer. Expert Review of Anticancer Therapy, 2019, 19, 739-755.	1.1	8
123	Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uroâ€Oncology. BJU International, 2019, 124, 221-241.	1.3	4
125	Postoperative radiation and hormonal therapy for men with nodeâ€positive prostate cancer: a new standard?. BJU International, 2019, 123, 199-200.	1.3	0
126	Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiotherapy and Oncology, 2019, 140, 68-75.	0.3	20
127	Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer. Urologia Internationalis, 2019, 103, 125-136.	0.6	23

#	Article	IF	Citations
129	The Role of Radical Prostatectomy and Lymph Node Dissection in Clinically Node Positive Patients. Frontiers in Oncology, 2019, 9, 1395.	1.3	7
130	Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. European Urology, 2019, 75, 817-825.	0.9	17
131	Circulating Tumor Cells as Surrogate Biomarker for Overall Survival in Metastatic Prostate Cancer. , 2019, , 565-572.		0
132	Pathologically Node-Positive Prostate Carcinoma â€“ Prevalence, Pattern of Care and Outcome From a Population-Based Study. Clinical Oncology, 2019, 31, 91-98.	0.6	5
133	Impact of ⁶⁸Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. Journal of Nuclear Medicine, 2019, 60, 963-970.	2.8	44
134	Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging?. European Urology, 2019, 75, 355-357.	0.9	6
135	Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study. European Urology Focus, 2019, 5, 1007-1013.	1.6	79
136	Adjuvant radiation with androgenâ€deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit. BJU International, 2019, 123, 252-260.	1.3	34
137	⁶⁸Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery. Acta OncolÃ³gica, 2020, 59, 149-156.	0.8	9
138	Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 204-209.	0.8	8
139	Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence. Clinical Genitourinary Cancer, 2020, 18, e112-e121.	0.9	8
140	Radiation Therapy for Prostate Cancer. Hematology/Oncology Clinics of North America, 2020, 34, 45-69.	0.9	33
141	The Horse is at the Stable Door: Management of N1M0 Prostate Cancer. Clinical Oncology, 2020, 32, 199-208.	0.6	3
142	Salvage Therapies After 18F-Fluciclovine Detected Prostate Cancer Recurrences. Clinical Nuclear Medicine, 2020, 45, 668-671.	0.7	3
143	The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 931.e1-931.e7.	0.8	5
144	A Nationwide Persistent Underutilization of Adjuvant Radiotherapy in North American Prostate Cancer Patients. Clinical Genitourinary Cancer, 2020, 18, 489-499.e6.	0.9	6
145	Whether extended pelvic lymph node dissection should be performed in prostate cancer: The present evidence from a systematic review and metaâ€analysis. Precision Medical Sciences, 2020, 9, 23-30.	0.1	2
146	Investigating the Benefit of Combined Androgen Modulation and Hypofractionation in Prostate Cancer. International Journal of Molecular Sciences, 2020, 21, 8447.	1.8	0

#	Article	IF	Citations
147	Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer. Cancer Medicine, 2020, 9, 6629-6637.	1.3	8
148	Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer. JAMA Oncology, 2020, 6, 1793.	3.4	10
149	Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. European Urology Oncology, 2020, 3, 565-581.	2.6	46
150	The Role of 68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Intermediate/High Risk Patients With Prostate Cancer: A Diagnostic Meta-Analysis. Frontiers in Oncology, 2020, 10, 1365.	1.3	16
151	Treatment of the primary in metastatic prostate cancer. Current Opinion in Urology, 2020, 30, 566-575.	0.9	4
152	Prostate cancer: more effective use of underutilized postoperative radiation therapy. Expert Review of Anticancer Therapy, 2020, 20, 241-249.	1.1	1
153	Adding radiotherapy to androgen deprivation therapy in men with node-positive prostate cancer after radical prostatectomy. Medicine (United States), 2020, 99, e19153.	0.4	3
154	Re: Effects of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with Dâ€™Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-institutional Study. European Urology, 2020, 77, 658-659.	0.9	0
155	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2020, 31, 1119-1134.	0.6	485
156	Nodal recurrence patterns on PET/CT after RTOG-based nodal radiotherapy for prostate cancer. Clinical and Translational Radiation Oncology, 2020, 22, 9-14.	0.9	7
157	Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. European Urology Oncology, 2021, 4, 948-954.	2.6	18
158	Pathologically Node-Positive Prostate Cancer. Cancer Journal (Sudbury, Mass), 2020, 26, 58-63.	1.0	1
159	Standardized and Simplified Robot-assisted Superextended Pelvic Lymph Node Dissection for Prostate Cancer: The Monoblock Technique. European Urology, 2020, 78, 424-431.	0.9	11
160	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancerâ€”2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 2021, 79, 243-262.	0.9	1,545
161	Technical Refinements in Superextended Robot-assisted Radical Prostatectomy for Locally Advanced Prostate Cancer Patients at Multiparametric Magnetic Resonance Imaging. European Urology, 2021, 80, 104-112.	0.9	22
162	The Role of Radiotherapy Among Patients With Prostate Ductal Adenocarcinoma. Clinical Genitourinary Cancer, 2021, 19, e41-e50.	0.9	3
163	KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2021, 24, 362-369.	2.0	8
164	Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. European Urology, 2021, 79, 595-604.	0.9	111

#	Article	IF	Citations
165	A DROP-IN Gamma Probe for Robot-assisted Radioguided Surgery of Lymph Nodes During Radical Prostatectomy. European Urology, 2021, 79, 124-132.	0.9	58
166	Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience. Prostate Cancer and Prostatic Diseases, 2021, 24, 514-523.	2.0	10
167	Oncological outcomes of pathologically organ-confined, lymph node-positive prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 234.e1-234.e7.	0.8	3
168	Postoperative Radiotherapy for Prostate Cancer. Practical Guides in Radiation Oncology, 2021, , 189-207.	0.0	0
169	A nomogram for predicting brain metastases of EGFR-mutated lung adenocarcinoma patients and estimating the efficacy of therapeutic strategies. Journal of Thoracic Disease, 2021, 13, 883-892.	0.6	5
170	Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. Prostate, 2021, 81, 286-294.	1.2	4
171	Phase I dose escalation trial of stereotactic radiotherapy prior to robotic prostatectomy in high risk prostate cancer. Reports of Practical Oncology and Radiotherapy, 2021, 26, 188-195.	0.3	0
172	Temporal Trends and Predictors in Diagnosing Pathologic Node-Positive Prostate Cancer in Clinically Node-Negative Patients. Clinical Genitourinary Cancer, 2021, , .	0.9	1
173	Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 830.e17-830.e26.	0.8	17
174	Narrative review of management strategies and outcomes in node-positive prostate cancer. Translational Andrology and Urology, 2021, 10, 3176-3187.	0.6	3
175	Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time?. Frontiers in Surgery, 2021, 8, 691473.	0.6	5
176	Elective nodal radiotherapy in prostate cancer. Lancet Oncology, The, 2021, 22, e348-e357.	5.1	26
177	Radiation treatment in prostate cancer: covering the waterfront. BJU International, 2021, 128, 398-407.	1.3	3
178	Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy. PLoS ONE, 2021, 16, e0256778.	1.1	1
179	Extended robotâ€assisted laparoscopic prostatectomy and extended pelvic lymph node dissection as a monotherapy in patients with very highâ€risk prostate cancer Patients. Cancer Medicine, 2021, 10, 7968-7976.	1.3	3
180	Prostate cancer: Molecular imaging and MRI. European Journal of Radiology, 2021, 143, 109893.	1.2	6
181	Title is missing!. , 2017, , .		3
184	The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients. Oncotarget, 2017, 8, 79279-79288.	0.8	19

#	Article	IF	Citations
185	Lymph node ratio determines the benefit of adjuvant radiotherapy in pathologically 3 or less lymph node-positive prostate cancer after radical prostatectomy: a population-based analysis with propensity-score matching. Oncotarget, 2017, 8, 110625-110634.	0.8	11
186	Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial. JMIR Research Protocols, 2018, 7, e11256.	0.5	12
187	External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer. Central European Journal of Urology, 2020, 73, 19-25.	0.2	7
188	Role of Locoregional Treatment in Vulvar Cancer With Pelvic Lymph Node Metastases: Time to Reconsider FIGO Staging?. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 922-930.	2.3	4
189	Multimodality Treatment for Patients with Node-Positive Prostate Cancer: the Role of Radiation Therapy. Asian Pacific Journal of Cancer Prevention, 2016, 17, 1625-1630.	0.5	2
190	Rationale of Surgery in Locally Advanced and Oligometastatic Prostate Cancer. The Korean Journal of Urological Oncology, 2016, 14, 97-108.	0.1	0
191	Postoperative Irradiation: Immediate or Early Delayed?. , 2017, , 231-250.		0
193	Evaluation and Treatment for High-Risk Prostate Cancer. , 2018, , 135-156.		0
194	Radical Prostatectomy in the Metastatic Setting. , 2018, , 169-184.		0
196	Genitourinary Cancers. , 2019, , 313-359.		0
197	Treatment of Patients With High Risk Prostate Cancer. The Korean Journal of Urological Oncology, 2019, 17, 34-47.	0.1	0
198	Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and Multiparametric MRI for Pelvic Lymph Node Staging Prior to Radical Prostatectomy in Patients With Intermediate to High-Risk Prostate Cancer: A Meta-Analysis. Frontiers in Oncology, 2021, 11, 737989.	1.3	13
199	Management of Men With Lymph Node Metastases Following Radical Prostatectomy: What Is the Optimal Treatment Strategy?: NYU Case of the Month, March 2020. Reviews in Urology, 2020, 22, 37-39.	0.9	0
200	Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence. Current Opinion in Urology, 2022, 32, 69-84.	0.9	6
203	Narrative Review of the Post-Operative Management of Prostate Cancer Patients: Is It Really the End of Adjuvant Radiotherapy?. Cancers, 2022, 14, 719.	1.7	1
204	Nomograms for metastasis-free and overall survival for pathologically node positive prostate cancer patients treated with or without radiation therapy plus short-term ADT. Clinical Genitourinary Cancer, 2022, , .	0.9	1
205	Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death. Journal of Clinical Oncology, 2022, 40, 2186-2192.	0.8	14
206	Acceptance and efficacy of recommended adjuvant radiotherapy in patients with positive lymph nodes at radical prostatectomy: a preference-based study. World Journal of Urology, 2022, 40, 1463-1468.	1.2	2

#	Article	IF	Citations
207	Radiation therapy after radical prostatectomy is associated with higher other-cause mortality. Cancer Causes and Control, 2022, 33, 769-777.	0.8	1
208	99mTc-PSMA targeted robot-assisted radioguided surgery during radical prostatectomy and extended lymph node dissection of prostate cancer patients. Annals of Nuclear Medicine, 2022, 36, 597-609.	1.2	6
209	THE ROLE OF LYMPHADENECTOMY IN PROSTATE CANCER PATIENTS.. Acta Clinica Croatica, 2019, 58, 24-35.	0.1	0
210	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. Medical Oncology, 2022, 39, 63.	1.2	6
211	Radiotherapy plus androgen deprivation therapy for prostateâ€specific antigen persistence in lymph nodeâ€"positive prostate cancer. Cancer Science, 2022, 113, 2386-2396.	1.7	8
212	Patients with Positive Lymph Nodes after Radical Prostatectomy and Pelvic Lymphadenectomyâ€"Do We Know the Proper Way of Management?. Cancers, 2022, 14, 2326.	1.7	2
213	Characteristics of Patients in SPCG-15â€"A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer. European Urology Open Science, 2022, 41, 63-73.	0.2	3
214	Adjuvant Radiation for Pathologically Node-Positive Prostate Cancer: Evidence When Early Salvage May Not Be Early Enough. Journal of Clinical Oncology, 2022, 40, 2179-2182.	0.8	1
215	Association of Adjuvant Radiation Therapy With Long-Term Overall and Recurrence-Free Survival After Hepatectomy for Hepatocellular Carcinoma: A Multicenter Propensity-Matched Study. International Journal of Radiation Oncology Biology Physics, 2022, 114, 238-249.	0.4	5
217	Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics. Prostate Cancer and Prostatic Diseases, 2024, 27, 58-64.	2.0	1
218	Adjuvant Treatment Approaches after Radical Prostatectomy with Lymph Node Involvement. Asian Pacific Journal of Cancer Prevention, 2022, 23, 2279-2284.	0.5	0
219	Biochemical relapse predictive factors in patients with lymph node metastases during radical prostatectomy. Progres En Urologie, 2022, , .	0.3	1
220	Androgen deprivation therapy in localized prostate cancer. Current status and future trends. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2023, 47, 398-407.	0.2	0
221	Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy: Extended, of Course. European Urology Open Science, 2022, 44, 13-14.	0.2	2
222	Lymphadenectomy in Prostate Cancer: Technique and Outcomes. , 2022, , 305-349.		0
223	Single tertiary cancer center experience on the management of pT3b prostate cancer after robotic-assisted laparoscopic prostatectomy. Current Urology, 0, Publish Ahead of Print, .	0.4	0
224	Evaluating the Impact of Prostate Only Versus Pelvic Radiotherapy for Pathological Node-positive Prostate Cancer: First Results from the Multicenter Phase 3 PROPER Trial. European Urology Focus, 2023, 9, 317-324.	1.6	3
225	Adjuvant radiotherapy in patients with node-positive prostate cancer after radical prostatectomy. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0

#	Article	IF	Citations
226	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease. Progres En Urologie, 2022, 32, 1275-1372.	0.3	15
227	Oncologic outcomes of patients with lymph node invasion at prostatectomy and post-prostatectomy biochemical persistence. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0
228	Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy. Prostate Cancer and Prostatic Diseases, 2024, 27, 81-88.	2.0	4
229	The Changing Face of cN0M0 Prostate Cancer Being Found With pN+ After Surgery in the Contemporary Era: Results of an International European Survey on Disease Management. Clinical Genitourinary Cancer, 2023, 21, 416.e1-416.e10.	0.9	0
230	Neutrophil-to-lymphocyte ratio predicts nodal involvement in unfavourable, clinically nonmetastatic prostate cancer patients and overall survival in pN1 patients. Scientific Reports, 2023, 13, .	1.6	1
231	Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer. Prostate Cancer and Prostatic Diseases, 0, , .	2.0	1
232	ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer. Radiotherapy and Oncology, 2023, 183, 109544.	0.3	6
233	An analysis of PSMA-PET/CT-positive lymph node distribution and their coverage by different elective nodal radiation volumes in postoperative prostate cancer patients. Journal of Nuclear Medicine, 0, , jnumed.122.265159.	2.8	0
234	External Validation of Briganti and Memorial Sloan-Kettering Cancer Centre Nomograms for Predicting Lymph Node Invasion in the Indian Cohort of Patients with Prostate Cancer. Indian Journal of Surgical Oncology, 0, , .	0.3	1
242	Prostate cancer and elective nodal radiation therapy for cN0 and pN0â€”aÂnever ending story?. Strahlentherapie Und Onkologie, 2024, 200, 181-187.	1.0	0